EW vs. STE, ISRG, ZBH, ALGN, DXCM, COR, IQV, TAK, IDXX, and ALC
Should you be buying Edwards Lifesciences stock or one of its competitors? The main competitors of Edwards Lifesciences include STERIS (STE), Intuitive Surgical (ISRG), Zimmer Biomet (ZBH), Align Technology (ALGN), DexCom (DXCM), Cencora (COR), IQVIA (IQV), Takeda Pharmaceutical (TAK), IDEXX Laboratories (IDXX), and Alcon (ALC). These companies are all part of the "medical" sector.
STERIS (NYSE:STE) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.
Edwards Lifesciences has a net margin of 23.35% compared to Edwards Lifesciences' net margin of 10.48%. STERIS's return on equity of 23.56% beat Edwards Lifesciences' return on equity.
STERIS has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.
92.9% of STERIS shares are owned by institutional investors. Comparatively, 79.3% of Edwards Lifesciences shares are owned by institutional investors. 1.0% of STERIS shares are owned by insiders. Comparatively, 1.3% of Edwards Lifesciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Edwards Lifesciences had 17 more articles in the media than STERIS. MarketBeat recorded 23 mentions for Edwards Lifesciences and 6 mentions for STERIS. STERIS's average media sentiment score of 0.86 beat Edwards Lifesciences' score of 0.74 indicating that Edwards Lifesciences is being referred to more favorably in the news media.
Edwards Lifesciences has higher revenue and earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.
STERIS currently has a consensus target price of $239.60, indicating a potential upside of 4.17%. Edwards Lifesciences has a consensus target price of $88.00, indicating a potential downside of 5.23%. Given Edwards Lifesciences' stronger consensus rating and higher possible upside, research analysts plainly believe STERIS is more favorable than Edwards Lifesciences.
Edwards Lifesciences received 981 more outperform votes than STERIS when rated by MarketBeat users. Likewise, 71.93% of users gave Edwards Lifesciences an outperform vote while only 58.79% of users gave STERIS an outperform vote.
Summary
Edwards Lifesciences beats STERIS on 14 of the 18 factors compared between the two stocks.
Get Edwards Lifesciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Edwards Lifesciences Competitors List
Related Companies and Tools